|
|
Teaming Up to Treat Rett Syndrome: The Importance of Fostering a Multidisciplinary Approach to Patient Care
Target Audience
The educational design of this activity addresses the needs of neurologists, pediatric neurologists and specialty NP/PAs involved in the treatment of patients with Rett syndrome.
Program Overview
With newer therapies now available for the treatment of Rett syndrome, it is essential that the challenges of managing patients with rare diseases, such as Rett syndrome in resource-poor areas or “care deserts” be addressed.
Join a neurologist and a gastroenterologist from ... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to screen for multiple cancers simultaneously (ACS, 2024). Currently, numerous clinical trials are investiga... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States (ACS, 2024; Pinsky & Berg, 2012; USPSTF, 2024). Multicancer early detection (MCED) is a novel form of blood-based ca... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Alpha-1 Antitrypsin Deficiency (AATD) Case Studies and Expert Perspectives: Screening, Diagnosis, and Augmentation Therapy
Target Audience
The intended audience for this activity is pulmonologists, allergists, hepatologists, gastroenterologists, respiratory therapists, and other health care providers who screen and manage patients with alpha-1 antitrypsin deficiency (AATD).
Program Overview
Alpha-1 antitrypsin deficiency (AATD) is one of the most prevalent genetic diseases. It is an uncommonly diagnosed, potentially life-threatening genetic disorder that predisposes individuals to lung and/or liver disease. I... |
|
|
Simple Steps for Improving the Quality of Healthcare for Patients with Chronic Idiopathic Constipation
To ensure your patients with chronic idiopathic constipation (CIC) receive timely, appropriate interventions and the best possible care, clinicians need to better distinguish CIC from similar conditions. In addition, working together, clinicians and patients can make better choices among the many treatment options through shared decision-making (SDM) strategies to help achieve treatment goals.
This digital format provides a brief questionnaire to capture your current practices and delivers... |
|